CA2343321A1 - Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament - Google Patents

Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament Download PDF

Info

Publication number
CA2343321A1
CA2343321A1 CA002343321A CA2343321A CA2343321A1 CA 2343321 A1 CA2343321 A1 CA 2343321A1 CA 002343321 A CA002343321 A CA 002343321A CA 2343321 A CA2343321 A CA 2343321A CA 2343321 A1 CA2343321 A1 CA 2343321A1
Authority
CA
Canada
Prior art keywords
drug
enzyme
pro
patient
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002343321A
Other languages
English (en)
Inventor
Alfred Slanetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of CA2343321A1 publication Critical patent/CA2343321A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques destinées au prétraitement d'un patient nécessitant un médicament ou un promédicament, ce médicament ou ce promédicament étant surmétabolisé ou sous-métabolisé chez le patient. L'invention concerne également les utilisations de ces compositions pharmaceutiques.
CA002343321A 1998-09-21 1999-09-21 Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament Abandoned CA2343321A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15736698A 1998-09-21 1998-09-21
US09/157,366 1998-09-21
PCT/EP1999/006973 WO2000017366A2 (fr) 1998-09-21 1999-09-21 Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament

Publications (1)

Publication Number Publication Date
CA2343321A1 true CA2343321A1 (fr) 2000-03-30

Family

ID=22563414

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002343321A Abandoned CA2343321A1 (fr) 1998-09-21 1999-09-21 Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament

Country Status (5)

Country Link
EP (1) EP1115871A2 (fr)
JP (1) JP2002526510A (fr)
AU (1) AU6328099A (fr)
CA (1) CA2343321A1 (fr)
WO (1) WO2000017366A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408746C (fr) * 2000-05-17 2010-09-21 Patrick L. Iversen Phosphorodiamidate morpholino-oligonucleotide antisens pouvant servir d'inhibiteur du cytochrome p450 afin de moduler la pharmacocinetique d'un medicament
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
WO2023039187A1 (fr) * 2021-09-10 2023-03-16 ATAI Life Sciences AG Polythérapie par ibogaïne

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
AU713382B2 (en) * 1996-03-27 1999-12-02 Bavarian Nordic A/S Cytochrome P450 transducing retroviral vectors
WO1998017667A1 (fr) * 1996-10-18 1998-04-30 Wayne State University 6',7'-dihydroxybergamotine, inhibiteur de cytochrome p450 ans le jus de pamplemousse

Also Published As

Publication number Publication date
EP1115871A2 (fr) 2001-07-18
JP2002526510A (ja) 2002-08-20
WO2000017366A3 (fr) 2000-07-13
WO2000017366A2 (fr) 2000-03-30
AU6328099A (en) 2000-04-10

Similar Documents

Publication Publication Date Title
JP4321877B2 (ja) トランス―スプライスにより生成される治療用分子
US11377643B2 (en) Therapeutics for glycogen storage disease type III
US20110039785A1 (en) Polypeptide-nucleic acid conjugates and uses thereof
EP1495769B1 (fr) Transfert de gènes aux cellules musculaires au moyens du récepteur du mannose-6-phosphate
JP2018127463A (ja) 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
US7279326B2 (en) Composition for delivery of a mitochondrial genome to a cell
NZ500694A (en) Use of chimeric mutational vector (CMV), a macromolecule and a ligand for cell surface receptor adhesion molecule (clatherin) in gene therapy; the CMV vector derived from REC2 homologous pairing with Ustilago maydis
JP2002316997A (ja) 目的とするアニオン性物質を細胞に導入するための複合体
CA2343321A1 (fr) Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament
Córdoba et al. Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases
US11939600B2 (en) Compositions and methods for treating phenylketonuria
JP2011504375A (ja) 細胞の中に核酸を導入する医薬組成物及びその方法
WO2011087804A2 (fr) Compositions peptide-polynucléotide, et procédés de transfection d'une cellule avec de l'adn et traitement d'une maladie neurodégénérative
EP1890711A1 (fr) Composés pour le traitement ou la prévention de pathologies ou de troubles liés à l amine oxydase
US5959078A (en) Isolated polysialyl transferases
WO2019207167A1 (fr) Thérapie de déficiences en sulfatase
US8093369B2 (en) Compositions for silencing the expression of VDAC1 and uses thereof
EP4197559A1 (fr) Complexe d'arnsi/de protéine immunomodulatrice présentant une activité anticancéreuse
JP4330269B2 (ja) 細胞層を通過する傍細胞輸送を促進する組成物および方法
CN114126668A (zh) 用于血色素沉积症治疗的组合物和方法
US20120164730A1 (en) Compositions for silencing the expression of vdac1 and uses thereof
CA2949345C (fr) Petit arn interferent (arnsi) utilisable en vue du traitement de l'osteoporose autosomique dominante de type 2 (ado2) provoquee par une mutation du gene clcn7 (ado2 dependant de c lcn7)
Prasmickaite et al. Light-directed gene delivery by photochemical internalisation
Halloy Therapeutic Strategies for the Treatment of Erythropoietic Protoporphyria
Monfrini et al. Unleashing the potential of mRNA therapeutics for inherited neurological diseases

Legal Events

Date Code Title Description
FZDE Dead